key: cord-0970249-7j6jqqb0 authors: Mantero, Vittorio; Abate, Lucia; Basilico, Paola; Balgera, Roberto; Salmaggi, Andrea; Nourbakhsh, Bardia; Cordano, Christian title: COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis date: 2020-06-25 journal: J Neurol DOI: 10.1007/s00415-020-10015-1 sha: 618a1586ebe53622354ec0621b81e4f34b8f6408 doc_id: 970249 cord_uid: 7j6jqqb0 nan Here, we would like to draw attention to another oral DMT. We report a case series of seven patients treated with dimethyl fumarate (DMF) that developed a self-limiting COVID-19 infection, during the peak of COVID cases in Lecco's province between March and May 2020. The diagnosis was based on the typical symptoms of COVID-19 infection (dry cough, anosmia, ageusia, fever, asthenia, and shortness of breath, see Table 1 ), associated with contacts with COVID-19-confirmed or suspected (respectively in 5 and 1 cases) subjects. Nasal swab and chest X-ray/CT were not performed due to the local guidelines at the time. All patients continued their therapy with DMF, and none of them experienced an MS relapse. Clinical characteristics and hematological values are reported in Table 1 . Patients were mostly female (71%), with an average age of 35.9 (± 11.4) years and a disease duration of 6.71 (± 5.6) years. Median EDSS was 1.5 (range 1. , and the average time on treatment with DMF was 2.4 (± 1.9) years. None had severe lymphopenia, and only one patient had grade two lymphopenia (0.67 ×10 3 /μL). No patient required hospitalization, ICU care, or intubation. They all improved without receiving any specific treatment. One of the patients reported left hand paresthesia during the respiratory symptoms, interpreted as a pseudo-relapse by the treating neurologist. To date, there are no reported cases of COVID-19 infections in DMF-treated patients. The mechanism of action of DMF has still not been fully elucidated, and may be mediated both by nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-dependent and independent pathways [11, 12] . DMF mechanism of action includes promotion of Th1-Th2 shift, induction of mild apoptosis of memory T cells and B cells, modulation of microglia activation, and neuroprotective effect by upregulation of Nrf2-dependent antioxidant response [13] [14] [15] [16] . These immunomodulatory effects may be protective against the cytokine storm [17] in patients infected with SARS-COV-2, which has been postulated as one of the mechanisms underlying a more severe disease. Bardia Nourbakhsh and Christian Cordano have contributed equally to this work. On the other hand, DMF, by reducing the lymphocyte count in a subset of patient may theoretically increase their risk of COVID-19. In a post-marketing prospective study, 4-6% out of 886 MS patients exposed to DMT developed grade III lymphopenia [18] . Nonetheless, serious infections are rarely reported in DMF-treated patients and occurred in <5% of patients, with no association between lymphopenia and increased incidence of infection [19] . This study has several limitations. The diagnosis of COVID-19 was based on clinical symptoms. The small number of patients, their young age, and low EDSS; and the presence of only a single case with moderate lymphopenia limit the generalizability of these observations. As it has been reported for other MS DMTs, our case series suggest that continuing treatment with DMF might be safe in young and non-lymphopenic MS patients who develop COVID-19 infection, and its interruption does not seem to be necessary. Brownlee et al. [20] suggest that during the COVID-19 pandemic, it is perhaps safe to start DMF in children and young adults who are otherwise healthy. In patients already on treatment, they suggest continuing treatment and ensure that lymphocyte count is higher than 500-800/mm 3 . These data give an insight into the management of MS patients during the COVID-19 pandemic, but further studies are necessary to confirm this preliminary observation, particularly in older, more disabled patients with significant co-morbidities. Author contributions VM contributed to the conceptualization, gathering of data, and drafting the manuscript; RB, LA, and PB contributed to gathering of data and drafting the manuscript; AS, BN, and CC contributed to drafting and revising the manuscript. Conflicts of interest VM, LA, and RB served in advisory boards and/ or received travel grant from Biogen for participation at congress. PB, AS, BN, and CC have no conflict of interest to disclose. Ethical approval All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent All patients provided consent to be anonymously included in this report. Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role An Italian programme for COVID-19 infection in multiple sclerosis Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies Infection as an environmental trigger of multiple sclerosis disease exacerbation Infection-related health care utilization among people with and without multiple sclerosis Bakshi R (2020) COVID-19 in Teriflunomide-Treated Patients With Multiple Sclerosis DEFINE Study Investigators Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2 IL-17(+) CD8(+) T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS COVID-19: consider cytokine storm syndromes and immunosuppression Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life. Spanish population Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic